Adjuvant Anti-PD-1 Scores Again in Melanoma

(MedPage Today) — Recurrence risk falls by more than 40% with pembrolizumab Source: Dermatology

(MedPage Today) — Recurrence risk falls by more than 40% with pembrolizumab
Source: Dermatology

Leave a Reply